Background: The aim of our study was to describe the lung cancer characteristics in lung transplant recipients at our institution.
| INTRODUC TI ON
From the beginning of the 1960s 1, 2 to the present day, lung transplantation (LTx) has been a validated treatment for end-stage lung diseases in rigorously selected patients. (31%), pulmonary fibrosis (30%), and cystic fibrosis (16%). 2 The 5-year survival rate has clearly improved, increasing from 46% in 1990
to 57% in 2015. 2 After the first year, the main causes of death in lung transplant recipients are lung graft dysfunction (40%), infections (20%), solid tumors (12%), and lymphoproliferative disorders (2%). 2 Several risk factors for cancer are present in this population.
First, in the general population, being over the age of 60 doubles the risk of lung cancer. 3 In 2016, 23.4% of recipients were older than 65. 2 Next, the smoking history of both the recipient and donor as well as environmental exposure such as to silica and asbestos are important risk factors. 2 Terminal respiratory illnesses qualifying for LTx such as COPD and pulmonary fibrosis are known to increase the risk of lung cancer 4, 5 as do immunosuppressive drugs. 6 The aim of our study was to describe the lung cancer characteristics of LTx recipients in our institution. given intravenous (IV) cyclosporine, azathioprine, and corticosteroids.
| ME THODS
Once digestive motility had recovered, the IV medication was switched to oral tacrolimus and mycophenolate mofetil (MMF) while corticosteroids were continued as before. From June 1, 2009, to August 2018, the protocol was modified to basiliximab as induction therapy followed by tacrolimus, MMF, and corticosteroids. This study was conducted according to the principles of the Declaration of Helsinki. All patients gave written informed consent for their inclusion in the study.
| RE SULTS
Between 1992 and 2017, 463 patients underwent LTx at our institution.
Among them, there were 361 bilateral LTxs, 75 single LTxs, and 27 heartlung transplantations. Altogether, 19 patients were diagnosed with lung cancer (4.10% of all LTxs), including eight cases of unexpected lung cancer in the native explanted lung (1.7%), eight in the native remaining lung (10.6% of the single LTxs), and three in the transplanted lung (0.64%) (Figure 1 ). Mean age at transplantation was 55.3 ± 6.6 years.
Of the patients, two were older than 65 years (10.5%) and 12 were between 50 and 64 (63.1%) ( 
| Lung cancer in the explanted lung
Demographics, tumor characteristics, and histopathological findings are summarized in Table 1 bilateral LTx, six for COPD, and two for pulmonary fibrosis. The median smoking history was 50 pack-years. Of the eight patients, The tumors in the explanted lungs were totally resected with pneumonectomy, and it was decided to pursue surveillance. Patient 6 had pleural invasion and was treated with chemotherapy after diagnosis. Patient 5 had a local recurrence 9 months after LTx and was treated with chemotherapy.
| Lung cancer in the transplanted lung
Three patients developed lung cancer in the transplanted lung.
One patient was transplanted for COPD and two for pulmonary However, the remaining lung was spared. Characteristics are shown in Table 2 .
| Lung cancer in the remaining native lung after single LTx
Eight patients had bronchogenic carcinoma in the native remaining lung. The indications for transplantation were COPD in four patients and pulmonary fibrosis in four. Median time between
LTx and diagnosis was 51.9 ± 33.0 months. All the patients in this group were former smokers with a mean smoking history of 31 pack-years. They are all dead. Overall survival after diagnosis was 8.25 ± 9.5 months ( 
| D ISCUSS I ON

| Prevalence
The prevalence of lung cancer diagnosed during follow-up was 2.37% in our center. This figure is concordant with other data in the literature. For example, according to the Organ Procurement Transplant Network/United Network for Organ Sharing database, 10 908 LTxs were performed in the United States between 1999 and 2008. In these, the prevalence of lung cancer was 2.03%. 7 In that study, median time between LTx and diagnosis was 1074 (905 to 1218) days, whereas it was 1611 days (365 to 3222) in our center.
The prevalence of incidental cancer in explanted lungs was 1.7%
in our study. This is in line with previously reported incidences, which have ranged from 0.8% to 2.2%. 8, 9 The prevalence of lung cancer in the native remaining lung in the literature was 1.9% 12,13,16,26 vs 1.7% in our study.
The overall prevalence of lung cancer following LTx was 4.10% in our study, which is again concordant with the prevalence of 3.88%
that we found in the literature. 7, 12, 25, 27 The prevalences reported in the medical literature are shown in Table 4 .
| Management of immunosuppressive therapy
There are no recommendations on the management of immunosuppression after the diagnosis of solid tumors in LTx recipients. Corticosteroids have been studied in the general population and seem to have a pro-oncogenic role. They are associated with an increased risk of squamous cell skin carcinoma and non-hodgkin lymphoma. 16 There are no data in the setting of LTx.
Calcineurin inhibitors seem to have a pro-oncogenic effect through the production of transforming growth factorβ1. 17, 18 Tacrolimus and cyclosporine have been compared, notably in renal transplantation. The difference between the two drugs in the development of solid tumors was not significant. 19 MMF was studied in 6751 renal transplant recipients and in an equal number of matched controls. There was no evidence of any increased risk of developing lymphoma or malignancy with MMF. clinical trial that enrolled 525 renal transplant recipients showed a lower risk of solid tumors with sirolimus and corticosteroids than with cyclosporine, sirolimus, and corticosteroids. 24 No data are available in LTx.
In the event of lung cancer following LTx, several authors decrease immunosuppression.
9,25
| Survival
According to the ISHLT, median survival in LTx is 6.0 years. After 1-year survival, the median is 8.1 years. 2 In our cohort, the estimated survival of bilateral LTx recipients with cancer in the explanted lung was lower (3.9 years). This finding may be due to the fact that surgery involved complete, curative resection for localized lung cancer, although the observation should be taken with caution given that median follow-up was short and different findings were presented in the literature. In the Toronto cohort, 13 lung cancers were found in 853 LTxs between 2003 and 2012.
Median survival was 339 days. Only four cases with stage I disease were found, and the other nine having more advanced-stage disease. 11 Another study on 852 LTx recipients found six cases of lung cancer. Those patients died between 5 and 35 months after transplantation. However, they had advanced localized disease, and one had lymphangitic carcinomatosis. 14 A study on 69 patients with lung cancer in the explanted lung showed that survival depends on the stage of the disease. The 5-year survival rate was 51% in patients with stage I disease, 14% in patients with stage II or III, and 23% in patients with multifocal bronchioloalveolar carcinoma. 10 Hence survival there was better with localized stages than advanced localized stages.
Nevertheless, the prognosis for LTx recipients with lung cancer in the transplanted or native remaining lung is poor. Indeed, median survival after diagnosis was 5 months (0 to 29) in our study. In their meta-analysis, Olland et al showed that such patients had a 1-year survival rate of between 25% and 33%. Their 2-year survival rate fell to 17%. 
TA B L E 4 (Continued)
The median estimated overall survival was 74.3 ± 16.3 months in our study, whereas it was 13.3 ± 14.8 months in the Mayo Clinic's cohort. 12 In our cohort, LTx patients who developed lung cancer had shorter overall survival (8.77 ± 0.74 years vs 6.19 ± 1.4 years in the lung cancer group). The result was significant on the log rank test (P = 0.042), but we must be careful with the interpretation of this result. Indeed, the survival curves cross and the lung cancer group was smaller than the LTx group without lung cancer.
| Preoperative detection of malignancy
Given the tumor recurrence rate after transplantation and the increased risk of mortality, preoperative detection of malignancy in the lung is decisive. Of the eight cases of lung cancer in the explanted lung in our study, five had suspicious nodes and only two underwent PET/CT. In a retrospective study, Strollo et al reviewed 22 preoperative chest CT examinations of patients who developed malignancy following transplantation. There were 17 lung cancers, three extrathoracic primary metastases, and two lymphoproliferative diseases. Twelve lung cancers were occult on the preoperative chest CT and corresponded to early-stage disease (I or II) for which surgery was curative. However, when lung cancer was suspected on the preoperative chest CT, the risk of recurrence was considerable.
The authors recommended chest CT within 3 months to evaluate CT abnormalities that mimic malignancy and assess for resolution or change. For nodes larger than 2 cm, they recommended discussing PET/CT, which frequently returned false positive results, and carefully performing biopsies given the poor lung reserve of the patients. 26 A PET scan cannot be performed in all LTx candidates given its cost and the fact that PET is not specific enough for nodes under 1 cm.
Moreover, lymph nodes were sampled during LTx. However, no complete lymph node dissection was performed in the patients, not even in the one with suspicious lesions on pre-LTx PET. A complete lymph node dissection was performed in patients if the lymph node was suspicious during the procedure.
| Therapeutic strategy
First, we should avert avoidable risk factors through prevention messages. In our study, smoking relapse after lung transplantation was found in three patients. Another study screened for smoking resumption in LTx recipients. In 331 patients, they found 39 active smokers (12%). The prevalence of oncological events was higher in the post-transplant smokers group. 27 Second, we saw that the prevalence of lung cancer in the remaining native lung after single LTx was 1.73%. Leaving one native lung behind in a population of smokers when performing single LTx for COPD or interstitial lung disease exposes patients to the risk F I G U R E 1 Flow chart of the study of cancer. Therefore, we should stress the importance of performing double LTx to prevent the development of lung cancer in the remaining lung in former smokers being treated with immunosuppression. Surgical resection can be a curative treatment and should be proposed for early-stage disease (stage I) if lung function is sufficient. 10 Indications for chemotherapy and radiotherapy follow the usual guidelines. However, the adverse effects of immunosuppressive and prophylactic drugs (such as renal impairment and bone marrow toxicity) may complicate the use of chemotherapy.
| Limitations
Our study had several limitations. Our results are based on retrospective analysis and single-center data collection. However, all the data were available for our patients, and none were lost to follow-up.
| CON CLUS ION
A diagnosis of lung cancer following LTx remains rare.
The detection of lung cancer in the explanted lung seems to have no impact on survival for early-stage lung cancer patients. However, lung cancer in the transplanted or native remaining lung after LTx has poor prognosis.
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